Drug profile · INN
ranibizumab
LUCENTIS
ranibizumab (LUCENTIS) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Drug details — ranibizumab
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- INJECTION
- Patents
- 0
- Programs
- 17
- Data quality
- 0.84
Quick answer
ranibizumab (LUCENTIS) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor A inhibitor
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ranibizumab?
ranibizumab (LUCENTIS) is a vascular endothelial growth factor a inhibitor. Associated with Novartis Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ranibizumab?
LUCENTIS is a marketed brand name for ranibizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranibizumab?
ranibizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.